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Abstract 
The effects of retinoic acid on components of the cAMP-dependent signalling system were examined in two related human 
neuroblastoma cell lines SK.-N-SH-F (SHF) and SK-N-SH-N (SHN). Retinoid treatment for a week significantly increased the 
concentration f intracellular cAMP and the levels of activity of protein kinase A and adenylate cyclase in both cell lines. Retinoic acid 
treatment also caused a very marked translocation of nucleoside diphosphate kinase from the cytosol to the membrane fraction. The 
increases in cyclic nucleotide and protein kinase A activity were observed to occur as early as within 1 and 2 days respectively and 
preceded or were concurrent with the onset of observable morphological differentitation. Results also indicated that agents which elevated 
intracellular cAMP caused neuronal differentiation and blunted retinoic acid-induced melanocytic differentiation in SHF cells. However, 
increases in cAMP brought about by treatment of SHF cells with retinoic acid alone were several-fold smaller and thus insufficient o 
induce neuritogenesis n these cells. The results as a whole indicate that one overall effect of retinoic acid treatment is to upgrade the 
activity of components of the cAMP-dependent signalling system in both neuroblastoma cell lines. However, retinoic acid causes the 
SH-F and SH-N cell lines to differentiate along different routes which means that the upgrading responses may be related to more general 
aspects of differentiation rather than to specific phenotype expression. 
1. Introduction 
Neuroblastoma cells can differentiate along several 
pathways to phenotypes possessing neuronal, schwannian 
or melanocytic haracteristics [1-4]. Interestingly, several 
neuroblastoma cell lines have been shown to display more 
than one potential, differentiating to neuronal or non-neu- 
ronal cells, depending on the conditions [3,5,6]. This was 
found to be the case with the human neuroblastoma cell 
line, SK-N-SH-F (SHF cells), which, cultured in the pres- 
ence of retinoic acid, differentiates to flat cells possessing 
melanocytic traits and which, when exposed to stau- 
rosporine, matures along the neuronal route. On the other 
hand, the related cell line, SK-N-SH-N, displays neuronal 
differentiation when either of these agents is present in the 
culture medium [7,8]. 
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With both animal and human neuroblastoma cell lines, 
it was demonstrated that addition of cyclic adenosine 
monophosphate (cAMP) derivatives, or agents that elevate 
intracellular cAMP such as forskolin and isobutylmethyl- 
xanthine, reduces growth rate and causes neuritogenesis 
[1,9-11]. Such agents were also found to restore the 
sensitivity of retinoic acid-resistant sublines of LA-N-5 
with respect to the neuronal differentiation response 
brought about by this retinoid [12]. The role of cAMP-de- 
pendent processes in neuronal differentiation is as yet not 
well understood. However, for neuroblastoma SH-SY-5Y 
cells, it was shown that PKA and PKC activation have 
opposing effects on neuritogenesis, the former promoting 
and the latter inhibiting neuritogenesis, but it was sug- 
gested for this cell line that the two protein kinases may 
function cooperatively during neuritogenesis [13]. Indeed, 
there is mounting evidence for such cross-talk between 
these two signalling systems. Accordingly, in several cell 
lines a down-regulation of the phospholipase C/protein 
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kinase C signalling cascade by protein kinase A was 
demonstrated [14-18]. Furthermore, it is known that 
changes in the levels of protein kinase C activity accom- 
pany differentiation of neuroblastoma cells [7,19,20] and 
that such changes can induce differentiation a d neuritoge- 
nesis [21]. 
The foregoing evidence points to a likely important role 
played by protein kinase A in the induced differentiation 
of neuroblastoma cells, probably through the regulation of 
protein kinase C activity. Treatment of SHF and SHN cells 
with retinoic acid respectively increases and decreases the 
levels of the C kinase activity in these ceils and causes 
very different differentiation phenotypes to appear [7]. The 
enhanced protein kinase C activity in SHF cells might well 
be linked to a decrease in protein kinase A activity and an 
inverse situation might result in SHN cells. Such distinct 
changes in the two cell lines could constitute one of the 
factors involved in the regulation of phenotype expression. 
In view of this, it became important to assess in these cells 
the effects of retinoic acid on components of the cAMP- 
dependent signalling system. We now report on how 
retinoic acid affects such parameters as cAMP, protein 
kinase A, adenylate cyclase and nucleoside diphosphate 
kinase. The latter enzyme plays a crucial role in the 
generation of GTP and the activation of adenylate cyclase 
[22,23] and thus can be considered part of the cAMP-de- 
pendent signalling system. We also evaluate observed 
changes in terms of their possible role in retinoic acid-in- 
duced differentiation and the distinct phenotypes expressed 
in SHF and SHN cells. 
2. Materials and methods 
All tissue culture products were purchased from GIBCO 
Laboratories (St. Louis, MO). All t rans retinoic acid, 
forskolin, 1-isobutyl-3-methylxanthine, staurosporine and 
N602-dibutyryl-cAMP were obtained from Sigma Chemi- 
cal Co. (St. Louis, MO). Adenosine 5'-triphosphate-y-[32p] 
([32p]ATP) was purchased from New England Nuclear, 
Mississauga, ON). Cyclic AMP binding assay kits were 
purchased from Amersham (Oakville, ON) and used as 
described by this supplier. 
SK-N-SH-F (SHF) and SK-N-SH-N (SHN) cells were 
cultured in RPMI 1640 medium supplemented with 5% 
fetal calf serum, 5% newborn calf serum and 1% v /v  
antibiotics/antimycotics solution (GIBCO), in a 5% CO 2, 
humidified atmosphere. For studies involving changes in 
morphology or determinations of cellular cAMP, 1.5.105 
cells were inoculated in 35-mm dishes and treated for up 
to 7 days with retinoic acid (3.3 /zM), dibutyryl cAMP (1 
mM), forskolin (10/zM) + isobutylmethylxanthine (1 /~M) 
or combinations of retinoic acid with dibutyryl cAMP or 
with forskolin and isobutylmethylxanthine. Controls were 
solvent reated (< 0.2% ethanol or dimethylsulfoxide). For 
assay of protein kinase A, adenylate cyclase and nucleo- 
side diphosphate kinase, 150-mm dishes were inoculated 
with 2 × 106 cells and treated agents (3.3 /~M retinoic 
acid, 15 nM staurosporine or combinations of these two 
agents for 7 days. Usually, the cultures were replenished 
every 3.5 days with fresh media containing the agents. 
When 6-day measurements of cAMP were made, changes 
of medium were on the third and fifth days. 
Total protein kinase A was assayed according to the 
method of Prashad et al. [24]. Briefly, the assay consisted 
of a measurement of [32p]phosphate incorporation into 
histone in the presence of labelled ATP with and without 
the addition of cAMP. The difference due to the cyclic 
nucleotide was ascribed to protein kinase A. A linear time 
course was obtained for 5 rain using 20 ~g of cell extract 
protein. Protein was determined by the method of Bradford 
[25]. 
Assay of adenylate cyclase was essentially as described 
by Franks et al. [26]. For this purpose, cells, washed with 
phosphate-buffered saline, were homogenized in 50 mM 
Tris-HC1 (pH 7.4) containing 330 mM sucrose, l mM Mg 
C] 2 and 1 mM dithiothreitol. The homogenate was cen- 
trifuged at 20000 g for 20 min and the pellet was 
resuspended in 0.5 ml of homogenization buffer. Enzyme 
activity was measured with an aliquot containing 50 /~g 
cell particulate protein added to a reaction mixture contain- 
ing 50 mM Tris-HCl buffer (pH 7.4), l0 mM MgC12, 2 
mM dithiotreitol, 2 mM cAMP, 0.01 /zCi [3H]cAMP, 0.5 
mM ATP + 0.5 /xCi y-[32p]ATP, 0.015% bovine serum 
albumin and as ATP-regenerating system consisting of 5 
mM phosphocreatine and 0.4 mg/ml phosphocreatine ki- 
nase. The final assay volume was 110 /~1. The reaction 
was initated by addition of enzyme and incubation was for 
6 rain at 37 ° C. The reaction mixture was terminated by 
addition of 0.6 ml water and 0.1 ml of 10 mM ATP. 
For assay of cAMP, cell lysates were prepared as 
described by Lando et al. [12]. Briefly, cells were washed 
twice with phosphate-buffered saline and harvested in 1 ml 
ice-cold phosphate-buffered saline containing 0.05 ml 0.1 
mM isobutylmethylxanthine. After centrifugation for 5 min 
at 5000 ×g,  the pellets were resuspended in 200 /.tl 
ice-cold 0.05 mM Tris buffer (pH 7.4), containing 4 mM 
EDTA and 0.1 mM isobutylmethylxanthine. C lls were 
lysed with two rapid freeze-thaw cycles followed by heat- 
ing for 3 rain in a boiling water bath. This was followed by 
centrifugation for 10 min at 12000 × g. The cAMP in the 
supernatant was measured with a competitive protein bind- 
ing assay kit as described by the supplier (Amersham, 
Canada Ltd.). 
Nucleoside diphosphate kinase was measured as de- 
scribed [27]. Briefly, 450/zl of a cell suspension (0.4 • 106 
cells/ml) were centrifuged at 280 × g for 5 rain at 15 ° C, 
washed twice with non-supplemented RPMI medium and 
frozen at -70  ° C. Cell pellets were thawed at 37°C and 
resuspended in two volumes of phosphate buffer A (potas- 
sium phosphate 50 mM [pH 7.0], MgCI z 2 raM, phenyl- 
methylsulfonyl fluoride 1 mM, dithioteitol 1 mM and 10% 
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Fig. 1. Effect of 3.3 /a,M retinoic acid on cAMP-dependent protein kinase 
of SHF cells as a function of time. 
glycerol. Cells were subsequently homogenized in a Poly- 
tron homogenizer (Brinkman Instruments, Rexdale, ON, 
Canada) set at 7.5 for 3 cycles of 10 s each. Between each 
cycle the samples tood on ice for 30 s. Homogenates were 
spun at 17 624 × g for 13 min at 4 ° and supernatants and 
particulate fractions (suspended in the original volume of 
buffer and sonicated) were kept at -70°C until further 
use. Fractions were extensively dialyzed against phosphate 
buffer A before measuring NDP kinase activity. For assay 
of the enzyme, 1-30 /zg of sample protein was placed on 
ice and 150 /xl of a solution containing 40 /xM deoxy 
GTP (donor), 200/xM deoxy ATP (acceptor) and 0.5 mM 
MgCI 2 was added followed by 15 /zl of 1 mM inosine 
solution. The mixture was then diluted to 300 /zl with 0.4 
M phosphate buffer and samples were incubated at 37°C 
for 10 min and subsequently boiled for 30 s. After filtra- 
tion through a 0.45-/~m filter (Acro LC 3A Gelman Sci- 
Fig. 2. Morphology of SHF cells treated with retinoic acid and cAMP-elevating agents. (a) Control SHF cells; treatment with: (b) 3.3 /xM retinoic acid; (c) 
1 mM dibutyryl cAMP; (d) 1 ~aM dibutyryl cAMP and 3.3 /zM retinoic acid; (e) 10 p,M forskolin combined with 1 /xM isobutylmethylxanthine; f) 
treatment with 3.3 /zM retinoic acid, 10 /xM forskolin and l /~M isobutylmethylxanthine. Bar = 25 /xm. 
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Table 1 
Effect of retinoic acid on protein kinase A activity 
Cellline Controlpmol/mg Retinoicacidtreated 
protein/min pmol /mgprotein/min 
SHF 20.55:1.8 34.8±3.0 
SHN 24.25:1.7 41.45:6.0 
Cells were treated with 3 × 10 -6 M retinoic acid or vehicle for 7 days. 
Values represent averages +S.E. (n = 7). P < 0.01 treated samples com- 
pared to control. 
Table 2 
Effect of retinoic acid on total cellular cAMP concentration 
Cell line cAMP concentration pmol /mg protein 
Control Retinoic acid-treated 
SHF 3.90 5:0.3 7.6 + 1.2 
SHN 2.56 5:0.03 4.50 5:0.03 
Cells were treated 7 days with 3.3X 10 -6 M retinoic acid. Values are 
averages_+S.E. (n= 3-4) P <0.004 for treated samples compared to 
control. 
Table 3 
Effect of retinoic acid on adenylate cyclase activity 
Cell line Activity (pmol/mg protein/6 min) 
Control Retinoic acid treated 
Basal Forskolin Basal Forskolin 
SHF 1755:16 18395:392 3885:58 28315:550 
SHN 226+69 461 5:189 23535:712 49185:1497 
Cells were treated 7 days with 3×10 -6 M retinoic and/or 10 p,M 
forskolin. Values represent + SE (n = 4) P < 0.01 for retinoic acid treated 
samples compared to corresponding controls. 
ences), 200 /zl of each sample was injected into Partisil 
SAX 10 /zM (Whatman International) analytical column 
(4.6 mm ID X 25 cm) connected to a precolumn (QMA 
anion exchanger, Millipore Waters). The column was equi- 
librated and eluted with 0.4 M ammonium phosphate [pH 
3.9] at a flow rate of 1 ml/min 1700-1800 psi). The 
detection of nucleotides was performed at 254 nm and 
their concentration estimated using as external standard, a
mixture of nucleotides (0.63-20.00 nmol). Ten nmol of 
inosine was used as internal standard. 
3. Results 
Results summarized in Table 1 reveal for both cell 
lines, enhancing effects of retinoic acid treatment on the 
levels of protein kinase A activity. These effects were 
followed as a function of time in SHF cells and became 
noticeable after 2 days while persisting for the 7 days 
under study (Fig. 1). Again in both cell lines, basal and 
forskolin-stimulated adenylate cyclase activities were found 
to be significantly increased after retinoic acid treatment 
(Table 2) as were also the cAMP levels (Table 3). Further- 
more, retinoic acid caused a very substantial increase of 
nucleoside diphosphate kinase activity in the stromal frac- 
tion and a loss in the cytosol fraction of these cells. 
Interestingly, no such translocation was seen when cells 
were treated with staurosporine only but it did occur in the 
presence of staurosporine and retinoic acid. Under the two 
conditions when staurosporine was present, a neuronal 
type of differentiation was induced as reported previously 
Table 4 
Effect of retinoic acid on nucleoside diphosphate activities of neuroblastoma cells 
Cell line Treatment Cytosol /~mol dATP/p,g Membranes/xmol dATP//zl  
SHF * control 0.60 5:0.03 1.33 5:0.14 
• retinoic acid (3.3/~M) 0.02 + 0.01 3.71 5:0.28 
• staurosporine (15 nM) 0.64 + 0.08 0.85 5:0.05 
• * staurosporine (15 nM) + retinoic acid (3.3/xM) 0.02 5:0 4.22 5:0,12 
SHN * control 0.52 5:0.02 1.42 + 0,08 
• retinoic acid (3.3 p,M) 0.03 _+ 0.01 5.92 5:0.26 
Results are expressed as means + S.E. ( * n = 4) ( * * n = 3). P < 0.001 for all retinoic acid-treated samples compared to non-treated controls. 
Table 5 
Effect of dibutyryl cAMP, forskolin, isobutylmethylxanthine a d retinoic acid on total intracellular cAMP concentration of SHF cells 
Conditions cAMP Concentration 
pmol /mg protein " 
Control (no addition) 
Retinoic acid (3.3/zM) 
Dibutyryl cAMP (1 raM) 
Dibutyrl cAMP (1 raM) + retinoic acid (3.3/xM) 
Forskolin (10/~M) 
Forskolin (10 p~M) + isobutylmethylxanthine (1 /zM) 
Dibutyryl cAMP (1 mM) + forskolin (10/xM) + isobutylmethylxanthine (1 /zM) 
Retinoic acid (3.3 /xM) + dibutyryl cAMP (1 mM) + forskolin (1 /xM) + isobutylmethylxanthine (1 /zM) 
2.65 5:0.0 
4.9 5:0.3 
16.3 5:1.3 
17.5 5:0.5 
17.1 5:0.1 
18.6 5:0.2 
20.3 5:1.1 
21.5 5:0.5 
* Values are averages + range of 2 experiments determined in triplicate. 
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[6,7]. It can be concluded then that translocation of the 
enzyme occurred provided retinoic acid was added, irre- 
spective of whether differentiation proceeded along the 
melanocytic route (SHF cells, retinoic acid alone) or the 
neuronal route (SHN cells, retinoic acid alone, or SHF 
cells, retinoic acid + staurosporine). 
The pluripotential SHF cell line displays undifferenti- 
ated morphology when grown under control conditions 
(Fig. 2a). Treatment of this, cell line with dibutyryl cAMP 
caused the cells to adopt somewhat more elongated, angu- 
lar shapes with an increase in short processes (2c). 
Forskolin + isobutylmethylxanthine caused neurites to ap- 
pear within 1-2 days (2e and 2f) and like dibutyryl cAMP, 
blunted the fiat cell, melanocytic type of differentiation 
brought about by retinoic acid alone in this same period of 
time (b). In fact, retinoic acid enhanced the neuritogenic 
effects of cAMP-elevating agents (d and f), possibly be- 
cause of increased protein kinase A activity. 
Results summarized in Tables 4 and 5 reveal the effects 
of retinoic acid, dibutyryl cAMP and cAMP-elevating 
agents, on the intracellular cAMP concentrations after 1 
day of treatment. As first reported by Lando et al. [12] 
working with retinoic acid resistant sublines of LA-N-5, 
we found that increases were generally more marked fol- 
lowing one day of treatment compared to those obtained 
with longer, 6-day periods of exposure to cAMP-elevating 
agents (results not shown). Even in one day a very signifi- 
cant increase in cAMP concentration occurred in retinoic 
acid treated cells as compared to controls. However, an 8- 
to 10-fold increase was nolted during this time period when 
dibutyryl cAMP or forskolin + isobutylmethyl-xanthine 
were added. Interestingly, retinoic acid potentiated the 
neuritogenic but not the cAMP-elevating effect of dibu- 
tyryl cAMP addition. Addition of all agents together only 
slightly increased cAMP concentrations above those ob- 
tained with dibutyryl cAMP or forskolin + 
isobutylmethylxanthine alone. 
4. Discussion 
The present study indicates that one effect of retinoic 
acid treatment in both cell lines is an upgrading of differ- 
ent constituents of the protein kinase A signalling system. 
Retinoic acid-induced inc:reases in protein kinase A activ- 
ity were also seen in other cell types including HL-60 cells 
[28], mouse F9 cells [29], mouse melanoma cells [30] and 
human embryonal carcinoma NT2/D1 cells [31]. The 
latter case is of particular interest since retinoic acid 
induces a large percentage of these cells to mature along 
the neuronal pathway and this is accompanied by an 
increase in protein kinase: A catalytic subunit mRNA and 
its translation product as well as a 7-fold increase in the 
total protein kinase A activity. 
The translocation of nucleoside diphosphate kinase to 
the membrane fraction during retinoic acid-induced differ- 
entiation of neuroblastoma cells has not been previously 
described although association of this enzyme with mem- 
brane has been observed in other types of cells [32,33]. 
The phosphotransferase ctivity of the membrane-bound 
nucleoside diphosphate kinase has been associated with an 
enhancement of guanine nucleotide-dependent adenylate 
cyclase activity most likely by sustaining GTP levels near 
the guanine nucleotide binding site [34-37]. In this regard, 
although the direct participation of nucleotide diphosphate 
kinase in the ATP-dependent transphosphorylation and 
activation of GDP bound to various G-proteins remains 
controversial [37], local transient GDP/GTP pools can be 
modulated by the activity of this enzyme. Such a mecha- 
nism could maintain the G-protein pool and G-protein-de- 
pendent enzymes in an activated state during highly dy- 
namic processes such as cell differentiation. Retinoic acid 
causes very different ypes of differentiation i SHF and 
SHN cells, processes that have been well characterized 
previously by ultrastructural, biochemical and histo-im- 
munochemical means [6-8]. Our results indicate that if the 
upgrading of cAMP-dependent signal transduction path- 
way plays an important role in differentiation f neuroblas- 
toma cells induced by retinoic acid, the enhanced levels of 
the signalling components are not linked to the develop- 
ment of one or the other of the phenotypes. They would be 
linked rather to early, more basic aspects of differentiation, 
since changes in cAMP levels occur within a day preced- 
ing or at the onset of observable morphological differentia- 
tion. 
Although there is evidence implicating protein kinase A 
in the differentiation of neuroblastoma cells [1,9-13], not 
all agents which cause differentiation of neuritogenic cells 
also cause significant increases of cAMP [38,39]. Results 
obtained in our laboratory (not shown) indicated that stau- 
rosporine which causes neuritogenesis in both cell lines 
has some inhibitory effect on protein kinase A and no 
effect on adenylate cyclase activity in vivo. Consequently 
up-regulation of this signalling system would be only one 
of the possible mechanisms that neuroblastoma cells might 
utilize to induce differentiation. 
There is mounting evidence obtained from several cell 
lines that protein kinase A down-regulates the protein 
kinase C signalling system [14-18] and that decreases in 
the activity of certain species of protein kinase C can lead 
to neuritogenesis [9,21]. Conversely, a down-regulation f
PKA might be expected to increase the basal and/or the 
receptor-stimulated activity of protein kinase C species. 
Since levels of protein kinase C activity increase in SHF 
cells as a result of retinoic acid treatment [7], we investi- 
gated the hypothesis that this was due to a down-regulation 
of the protein kinase A signalling components. Our results 
clearly dismiss this possiblity. 
Remarkably, neuritogenesis in SHF cells did not occur 
unless, when dibutyryl cAMP or forskolin + 
isobutylmethylxanthine were present, intracellular cAMP 
concentrations rose to levels several-fold greater than those 
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obtained with RA alone. Thus although increases in intra- 
cellular cAMP can give rise to neuritogenesis, a hallmark 
of neuronal differentiation in cell cultures, the levels 
reached during retinoic acid treatment of SHF cells are 
insufficient to provoke the growth of neuronal processes. It
is not known, however, whether in SHN cells the retinoid- 
induced increases in cyclic nucleotide (similar to those 
seen for SHF cells) are sufficient o cause the neuritogene- 
sis noted. Quite possibly, the differentiation to one or the 
other of the possible phenotypes in pluripotential neurob- 
lastoma cells, such as SHF cells, is dependent on the 
intracellular levels of cAMP attained under a given set of 
conditions. Indeed, it was reported for the SH-SY5Y cell 
line (derived from the SK-N-SH cell line as are also the 
cell lines used in the present study), that retinoic acid 
induces upgraded responses to prostaglandin El, resulting 
in a very marked rise in intracellular cAMP concentration 
and neuritogenesis [40]. These points and the role played 
by the cAMP-dependent signalling system in the differenti- 
ation of neuroblastoma cells need further investigation. 
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